Moberg begins patient enrolment in US and Europe Phase 3 onychomycosis trials
Moberg Pharma have begun patient enrolment in the US, Canada and Germany in the Phase 3 program investigating MOB-015 for the treatment of onychomycosis.
Click on this link for more information.
